ATE212226T1 - Gamma-rar antagonistligand oder alpha-rar agonistligand als apoptoseinhibitor - Google Patents

Gamma-rar antagonistligand oder alpha-rar agonistligand als apoptoseinhibitor

Info

Publication number
ATE212226T1
ATE212226T1 AT96933503T AT96933503T ATE212226T1 AT E212226 T1 ATE212226 T1 AT E212226T1 AT 96933503 T AT96933503 T AT 96933503T AT 96933503 T AT96933503 T AT 96933503T AT E212226 T1 ATE212226 T1 AT E212226T1
Authority
AT
Austria
Prior art keywords
ligand
rar
gamma
alpha
pct
Prior art date
Application number
AT96933503T
Other languages
English (en)
Inventor
Laszlo Fesus
Zsuzsa Szondy
Uwe Reichert
Original Assignee
Galderma Rech Dermatologique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Rech Dermatologique filed Critical Galderma Rech Dermatologique
Application granted granted Critical
Publication of ATE212226T1 publication Critical patent/ATE212226T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
AT96933503T 1995-10-11 1996-10-08 Gamma-rar antagonistligand oder alpha-rar agonistligand als apoptoseinhibitor ATE212226T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9511946A FR2739777B1 (fr) 1995-10-11 1995-10-11 Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
PCT/FR1996/001569 WO1997013506A1 (fr) 1995-10-11 1996-10-08 LIGANT ANTAGONISTE RAR-η OU AGONISTE RAR-α EN TANT QU'INHIBITEUR D'APOPTOSE

Publications (1)

Publication Number Publication Date
ATE212226T1 true ATE212226T1 (de) 2002-02-15

Family

ID=9483437

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96933503T ATE212226T1 (de) 1995-10-11 1996-10-08 Gamma-rar antagonistligand oder alpha-rar agonistligand als apoptoseinhibitor

Country Status (21)

Country Link
US (1) US6063797A (de)
EP (1) EP0854711B1 (de)
JP (1) JP3135267B2 (de)
KR (1) KR100300214B1 (de)
CN (1) CN1104896C (de)
AT (1) ATE212226T1 (de)
AU (1) AU695311B2 (de)
BR (1) BR9611035A (de)
CA (1) CA2231558C (de)
DE (1) DE69618802T2 (de)
DK (1) DK0854711T3 (de)
ES (1) ES2172680T3 (de)
FR (1) FR2739777B1 (de)
HU (1) HUP9900037A3 (de)
NO (1) NO981652L (de)
NZ (1) NZ319647A (de)
PL (1) PL186821B1 (de)
PT (1) PT854711E (de)
RU (1) RU2191008C2 (de)
TR (1) TR199800644T2 (de)
WO (1) WO1997013506A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
FR2776511B1 (fr) * 1998-03-31 2001-05-11 Galderma Rech Dermatologique Utilisation dans ou pour la preparation d'une composition d'au moins un inhibiteur de l'activite de l'acide retinoique
IL142094A0 (en) * 1998-09-29 2002-03-10 Gamida Cell Ltd Methods of controlling proliferation and differentiation of stem and progenitor cells
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6713515B2 (en) * 2000-09-13 2004-03-30 Bristol Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (de) * 2002-01-25 2006-06-07 Gamida Cell Ltd Verfahren zur expansion von stamm- und vorläuferzellen und damit erhaltene expandierte zellpopulationen
WO2006030442A2 (en) * 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
RU2007120254A (ru) * 2004-12-17 2009-01-27 Вайет (Us) Новые способы применения агонистов эстрогена бета
KR100798853B1 (ko) * 2005-02-15 2008-01-28 (주)한국스티펠 레티노이드를 유효성분으로 하는 백반증 예방 및 치료용 약학적 조성물
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US8082730B2 (en) * 2008-05-20 2011-12-27 Caterpillar Inc. Engine system having particulate reduction device and method
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
CN111773213B (zh) * 2010-09-01 2023-02-24 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
WO2013121426A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9861640B2 (en) 2013-06-10 2018-01-09 Kemphys Ltd. Medicament for treatment of Alzheimer's disease
WO2016144976A1 (en) * 2015-03-09 2016-09-15 Kings College London Combination therapy with rar alpha agonists for enhancing th1 response
EP3277272B1 (de) 2015-03-31 2021-08-04 Syros Pharmaceuticals, Inc. Verfahren zur stratifizierung von patienten zur behandlung mit retinsäurerezeptoragonisten
US20190112272A1 (en) * 2016-04-07 2019-04-18 High Force Research Limited Synthetic retinoids for use in rar mediated conditions
KR20240157122A (ko) 2016-04-08 2024-10-31 사이로스 파마수티컬스, 인크. Aml 및 mds 치료용 rara 효능제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
FR2713640B1 (fr) * 1993-12-15 1996-01-05 Cird Galderma Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
FR2722985B1 (fr) * 1994-07-27 1996-09-13 Cird Galderma Nouvelles compositions a base d'un melange synergetique entre au moins un ligand specifique des rxrs et au moins un ligand specifique de rar-x ou de vdr, et leurs utilisations

Also Published As

Publication number Publication date
NO981652L (no) 1998-06-10
ES2172680T3 (es) 2002-10-01
CA2231558C (fr) 2003-05-27
DK0854711T3 (da) 2002-03-25
HUP9900037A2 (hu) 1999-04-28
EP0854711A1 (de) 1998-07-29
HUP9900037A3 (en) 1999-11-29
DE69618802T2 (de) 2002-11-14
CA2231558A1 (fr) 1997-04-17
KR100300214B1 (ko) 2001-11-22
PL326162A1 (en) 1998-08-31
JPH11500448A (ja) 1999-01-12
NO981652D0 (no) 1998-04-08
WO1997013506A1 (fr) 1997-04-17
NZ319647A (en) 2000-06-23
AU7221096A (en) 1997-04-30
FR2739777A1 (fr) 1997-04-18
US6063797A (en) 2000-05-16
RU2191008C2 (ru) 2002-10-20
JP3135267B2 (ja) 2001-02-13
BR9611035A (pt) 1999-07-06
PL186821B1 (pl) 2004-03-31
AU695311B2 (en) 1998-08-13
TR199800644T2 (xx) 1998-07-21
CN1104896C (zh) 2003-04-09
CN1203529A (zh) 1998-12-30
FR2739777B1 (fr) 1997-11-14
DE69618802D1 (de) 2002-03-14
KR19990064204A (ko) 1999-07-26
EP0854711B1 (de) 2002-01-23
PT854711E (pt) 2002-05-31

Similar Documents

Publication Publication Date Title
DE69618802D1 (de) gamma-RAR ANTAGONISTLIGAND ODER alpha-RAR AGONISTLIGAND ALS APOPTOSEINHIBITOR
NO924619D0 (no) (+)-alfa-(2,3-dimetoksyfenyl)-1-(2-(4-fluorfenyl)ethyl)-4-piperidinmetanol
DK0624087T3 (da) Sprøjteafkølet nabumeton
DE69422304D1 (de) Cytokine antagoniste
ES2188983T3 (es) Nuevas benzofuran-4-carboxamidas.
EP0644486A3 (de) Verwaltung des Datenzugriffs in Computersystemen.
DE69719778D1 (de) Benzonaphthyridine als bronchialtherapeutika
NO910232D0 (no) Anordning ved stol.
ES2161279T3 (es) Nucleosidos y nucleotidos que contienen racimos de boro.
MX9203074A (es) 4-(1h-pirrol-1-il)-imidazoles con actividad antagonista de angiotensina ii.
NO932146L (no) Benzimidazolderivater
MX9606179A (es) Agonistas y antagonistas de los receptores del acido acetilcolina nicotinico de insectos para el control de endoparasitos.
ATE228760T1 (de) Thrombininhibitoren
DE59700895D1 (de) Ultraschall-tastaturschutz
ATE309352T1 (de) Inhibitoren der nf-kb aktivierung
FI915201A0 (fi) Arrangemang foer styrning av en ekoslaeckare.
ATE201869T1 (de) 4-((thien-2-yl)methyl)imidazolderivate mit alpha2-adrenoceptor agonistischer aktivität
ATE135188T1 (de) Gehörschutzstöpsel
GB9607119D0 (en) Compounds
FI941259L (fi) Uudet alfa-mannosidaasiestäjät
SE9703692D0 (sv) New use
DE69512086D1 (de) 1,4,4-(trisubstituierte)cyclohex-1-en-derivate als pde iv- und tnf-hemmer
NO934274D0 (no) Plate for bruk av datamus
KR970019240U (ko) 전화기능이 내장되는 퍼스널 컴퓨터의 키이보드
IT1255639B (it) Uso dell'oxatomide come agente antitosse

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee